modified Eagle's medium containing 10% fetal calf serum; III-mGluR, group III metabotropic glutamate receptor; II-mGluR, group II metabotropic glutamate receptor; LME, linear mixed effects
effects of NMDAR antagonists remain unclear. To explore the mechanisms by which MK801 and MEM affect thalamocortical transmission, we determined interactions between local administrations of MK801, MEM, system xc − (Sxc), and metabotropic glutamate receptors (mGluRs) on extracellular glutamate and GABA levels in the mediodorsal thalamic nucleus (MDTN) and medial prefrontal cortex (mPFC) using dual-probe microdialysis with ultra-high-pressure liquid chromatography. Effects of MK801 and MEM on Sxc activity were also determined using primary cultured astrocytes. Sxc activity was enhanced by MEM, but was unaffected by MK801.
MK801 enhanced thalamocortical glutamatergic transmission by GABAergic disinhibition in the MDTN. In the MDTN and the mPFC, MEM weakly increased glutamate release by activating Sxc, whereas MEM inhibited thalamocortical glutamatergic transmission. Paradoxical effects of MEM were induced following secondary activation of inhibitory II-mGluR and III-mGluR by exporting glutamate from astroglial Sxc.
The present results suggest that the effects of therapeutically relevant concentrations of MEM on thalamocortical glutamatergic transmission are predominantly caused by activation of Sxc rather than inhibition of NMDAR. These demonstrations suggest that the combination between reduced NMDAR and activated Sxc contribute to the neuroprotective effects of MEM. Furthermore, activation of Sxc may compensate for the cognitive impairments that are induced by hyperactivation of Abbreviations: ACSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; CPG, (S)-4-carboxyphenylglycine; CPPG, (RS)-α-cyclopropyl-4-phosphonophenyl glycine; fDMEM, Dulbecco's modified Eagle's medium containing 10% fetal calf serum; III-mGluR, group III metabotropic glutamate receptor; II-mGluR, group II metabotropic glutamate receptor; LME, linear mixed effects model; MDTN, mediodorsal thalamic nucleus; MEM, memantine; mGluR, metabotropic-glutamate receptors; mPFC, medial prefrontal cortex; MRS, modified Ringer's solution; MUS, muscimol; NAC, N-acetyl-L-cysteine; NMDAR, N-methyl D-aspartate receptor; RTN, reticular thalamic nucleus; Sxc, system cysteine/glutamate antiporter; UHPLC, ultra-high-performance liquid chromatography.
trast with NMDAR agonists, the NMDAR antagonists amantadine and memantine (MEM) improved cognitive impairments of schizophrenia according to another meta-analysis, 5 and adjuvant medication with MEM and antipsychotics was effective on positive, negative, and cognitive symptoms in schizophrenia. 6, 7 Other clinical studies demonstrate clinical benefits of MEM against several psychiatric disorders, including mood and anxiety disorders and schizophrenia. 8 The mechanisms behind the clinical discrepancies between psychotomimetic NMDAR antagonists and MEM remain poorly understood. Although MEM is predominantly considered a NMDAR inhibitor, 9 other pharmacological studies show that MEM inhibits 5-HT3, nicotinic α7, α4β2 receptors, monoamine oxidases, and transporters of serotonin and dopamine. [8] [9] [10] Preclinical studies similarly show attenuation of methylmercury-induced neurotoxicity by MEM, involving NMDAR antagonist and indirect antioxidant activities, and likely inhibition of the reduction of nonenzymatic (nonprotein sulfhydryl) and enzymatic (superoxide dismutase and glutathione peroxidase) antioxidants. 11 Glutathione is synthesized by glutamatecysteine ligase and glutathione synthase from cysteine, which is transported through the cystine/glutamate antiporter system xc − (Sxc). 12 MEM also had neuroprotective effects in patients with ischemic stroke 13 and quantitative proteomic analyses demonstrated that phencyclidine upregulated phosphorylation of the light chain of Sxc in the prefrontal cortex of rats, although the related kinase was not identified. 14 Based on these clinical and preclinical studies, we investigated the antipsychotic mechanisms of MEM with a special focus on the mPFC hyper-glutamatergic hypothesis of schizophrenia.
For this purpose, we (1) and GABA A receptor on thalamocortical transmission. These two studies were generated in analyses of thalamocortical glutamatergic transmission using dual-probe microdialysis experiments in freely moving rats with ultra-high-performance liquid chromatography (UHPLC). We then (3) determined the effects of MK801 and MEM on Sxc activity using primary cultured astrocytes.
| MATERIALS AND METHODS

| Chemical agents
NMDAR antagonist, MK801, 15 memantine (MEM), cysteine prodrug, N-acetyl-L-cysteine (NAC), 16 and the GABA A receptor agonist, muscimol (MUS) 15 were obtained from Wako Chemicals (Osaka, Japan).
The II-mGluR antagonist LY341495, 17 the III-mGluR antagonist (RS)-α-cyclopropyl-4-phosphonophenyl glycine (CPPG), 17 and the Sxc inhibitor (S)-4-carboxyphenylglycine (CPG) 18 were purchased from Tocris Bioscience (Bristol, UK).
All compounds were prepared on the day of experiments.
MK801, MEM, CPPG, CPG, NAC, and MUS were dissolved in modi- 
| Preparation of the microdialysis system
All animal care and experimental procedures were performed in compliance with the Ethical Guidelines established by the Institutional Eicom, Kyoto, Japan) and the MDTN (A = −3.0 mm, L = +0.9 mm, V = −6.2 mm, relative to bregma; 0.22 mm diameter, 2 mm exposed membrane: Eicom). 22 Following surgery, rats were housed individually in cages during recovery and experiments, and were provided food and water ad libitum.
Perfusion experiments were started after 18 hours recovery from isoflurane anesthesia. 19, 20 Rats were placed into a system for freely moving animals (EICOM) that was equipped with a two-channel swivel (TCS2-23; ALS, Tokyo, Japan). The perfusion rate was set at 2 μL min −1 in all experiments with MRS. 19, 20 Dialysates were collected every 20 minutes. 
| Microdialysis study design
Rats were randomly assigned to treatment in each experimental 
MUS to MRS containing the same agent with 50 μmol L −1 MK801
( Figure 3 ).
| Study-4
To clarify the mechanisms of mPFC MK801-induced glutamate rise, MDTN perfusate was switched to MRS containing 50 μmol L
the mPFC (Figure 4 ).
| Study-5
To clarify the mechanisms of the increase in glutamate level in MDTN induced by perfusion with 10 μmol L −1 MEM into MDTN (MDTN MEM-induced glutamate rise), MDTN perfusate was
MRS containing the same agent with 10 μmol L −1 MEM ( Figure 5 ).
| Study-6
To clarify the mechanisms of the increase in glutamate level in mPFC induced by perfusion with 10 μmol L −1 MEM into mPFC (mPFC MEM-induced glutamate rise), mPFC perfusate was switched from
taining the same agent with 10 μmol L −1 MEM ( Figure 6 ).
| Study-7
To determine the interaction among MEM and Sxc, II-mGluR, and IIImGluR in MDTN on mPFC MK801-induced glutamate rise and MDTN MK801-induced GABA reduction, MDTN perfusate was switched from MRS containing 10 μmol
MRS containing the same agent with 50 μmol L −1 MK801 (Figure 7 ).
OKADA ET AL. MK801, during perfusion with 10 μmol Figure 8 ).
| Primary astrocyte culture
Astrocytes were prepared using a protocol which was adapted from previously described methods. 19, 20, 26 Briefly, cortical astrocyte cultures were prepared from neonatal Sprague-Dawley rats (SLC; n = 30) that were sacrificed by decapitation at 0-24 hours of age and cerebral hemispheres were removed under a dissecting microscope. Tissues were then chopped into fine pieces using scissors and were triturated briefly using a micropipette. Suspensions were filtered using a 70 μm nylon mesh (BD, Franklin Lakes, NJ) and were then centrifuged. Pellets were resuspended and cen- were injected using auto sampler (xLC3059AS, Jasco). The analytical column (YMC Triat C18, particle 1.8 μm, 50 × 2.1 mm, YMC, Kyoto, Japan) was maintained at 45°C and the flow rate was set at 500 μL min 
| Determination of diffusion rates of MEM
To accurately measure MEM concentrations in brain tissue that were perfused into MDTN and mPFC, in vivo probe diffusion was determined according to a reverse dialysis procedure. 28, 29 Because solute diffusion occurs in both directions across dialysis membranes, loss of solute from the perfusate occurs at the same rate as recovery of the solute into the perfusate. During analyses, the temperature was maintained at 37°C with a perfusion warmer. The probe was set in the warmer chamber, and the MRS containing MEM was perfused into the probe for 180 minutes.
MEM levels were determined using UHPLC (PU-4185, Jasco, Tokyo, Japan) with a mass spectrometer (Acquity SQ detector, Waters, Milford, MA). Twenty microliter aliquots of filtered samples were injected by the auto sampler and concentrations of ) into the MDTN on releases of glutamate in the MDTN, GABA in the MDTN, glutamate in the mPFC, and GABA in the mPFC, respectively. Gray bars indicate the perfusion with MK801 and MEM into the MDTN. Microdialysis was conducted to measure the releases of L-glutamate and GABA. In (A, C, E, and G), ordinates: mean ± SD (n = 6) of extracellular levels of glutamate and GABA (μmol L −1 ), abscissa: time after administration of MK801 or MEM (min). (B, D, F, and H) indicate the AUC value of extracellular levels of glutamate and GABA (nmol) during perfusion with MK801 or MEM (from 0 to 180 minutes) of (A, C, E, and G), respectively. *P < 0.05; relative to control (black) by LME with Tukey's post hoc test MEM were determined using a UHPLC instrument equipped with a Triat C18 (particle 1.8 μm, 50 × 2.1 mm, YMC) column at 40°C, and the mobile phase was set at 500 μL min 
| Statistical analysis
All experiments were designed equal sizes (N = 6) per groups. The microdialysis study was compared with linear mixed effects model (LME) using SPSS for Windows (ver 25, IBM, Armonk, NY). When F I G U R E 3 A, C, and E, indicate interaction among perfusions with NAC (1 mmol L
) into the MDTN on releases of glutamate in the mPFC, glutamate in the MDTN, and GABA in the MDTN, respectively. Gray bars indicate the perfusion with NAC, CPG, LY341495, CPPG, and MUS, and open bars indicate perfusion with MK801into the MDTN. Microdialysis was conducted to measure the releases of L-glutamate and GABA. In (A, C, and F), ordinates: mean ± SD (n = 6) of extracellular levels of glutamate and GABA (μmol L −1 ), abscissa: time after administration of MK801 (minutes). B, D, and F, indicate the AUC value of extracellular levels of glutamate and GABA (nmol) during perfusion with MK801 (from 0 to 180 minutes) of (A, C, and F), respectively. Especially, gray columns of (D) indicate the AUC values of basal extracellular glutamate level of (C). *P < 0.05; relative to MK801 alone (black) by LME with Tukey's post hoc test. # P < 0.05; relative to levels of MK801 pre-perfusion of control by LME with Tukey's post hoc test the F-value of drug factor was significant, the data were analyzed by Tukey's post hoc test using BellCurve for Excel (Social Survey Research Information Co., Ltd., Tokyo, Japan). To represent the statistical significance of drug factor compared with LME and Tukey's post hoc test, the data (levels of L-glutamate and GABA) were The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology. MEM into the mPFC had no effects, whereas that with 10 μmol L −1 MEM increased glutamate levels in the mPFC ( Figure 1A and B). In contrast with glutamate, perfusions of MK801 into the mPFC concentration-dependently decreased extracellular GABA levels in the mPFC (mPFC MK801-induced GABA reduction), whereas perfusion with MEM had no effects ( Figure 1C and D). ; III-mGluR antagonist) affected mPFC MK801-induced glutamate rise ( Figure 3A and B).
Neither perfusions with MK801 (50 μmol L −1 ), CPG (1 μmol
(1 μmol L −1 ) into the MDTN affected glutamate levels in the MDTN, whereas perfusion with NAC (1 mmol L −1 ) into the MDTN increased basal glutamate levels in the MDTN (P < 0.05; Figure 3C and D).
Perfusion with MK801 into MDTN decreased the extracellular GABA level in the MDTN (MDTN MK801-induced GABA reduction), and these were not affected by perfusions with NAC (1 mmol L −1 ),
) into the MDTN ( Figure 3E and F).
| Effects of Sxc, II-mGluR, III-mGluR, and
GABA A receptor in the mPFC on mPFC MK801-induced glutamate rise ), CPPG (100 μmol
) into mPFC affected mPFC MK801-induced glutamate rise ( Figure 4A and B) . 
| Effects of Sxc, II-mGluR, III-mGluR, and GABA A receptor in the mPFC on mPFC MEMinduced glutamate rise
Perfusion with NAC (1 mmol L −1 ) into mPFC increased extracellular glutamate level in mPFC, whereas neither perfusion with ), but no effects of MK801 were observed under these conditions ( Figure 9B ).
| DISCUSSION AN D CONCLUSIONS
| Effects of MK801 on thalamocortical glutamatergic transmission
Several microdialysis studies show that systemic administration of the noncompetitive NMDAR antagonists phencyclidine, ketamine, and MK801 increased glutamate release in the mPFC. 23, [31] [32] [33] However, local administration of MK801 into the mPFC did not affect glutamate levels in the mPFC. 19, 23, 29, [34] [35] [36] In contrast with observations in the mPFC, inhibition of NMDAR in the MDTN induced by local administration of MK801 into the MDTN increased glutamate release in the mPFC (mPFC MK801-induced glutamate rise). 23 The present study showed that perfusion of MK801 into the MDTN also increased glutamate release from the mPFC without affecting that in the MDTN. These results suggest that the major mechanisms of systemic NMDAR antagonist-induced glutamate release in the mPFC are generated by enhanced thalamocortical glutamatergic transmission outside of the mPFC. 23 Glutamatergic neurons in the MDTN, which receive GABAergic terminals from the reticular thalamic nucleus (RTN) and other MDTN regions, project to superficial layers in the frontal cortex. [37] [38] [39] Moreover, thalamocortical glutamatergic terminals activate catecholaminergic terminals, but do not make contact with cortical GABAergic neurons. 35, 36 However, a large proportion of the GABAergic neurons in the frontal cortex are regulated by excitatory glutamatergic transmission from other cortical regions via activation of NMDAR. 23, 35, 40, 41 Given these anatomical observations, we characterized the mechanisms of systemic MK801-induced glutamate release in the mPFC by determining the effects of MK801 perfusions into the MDTM and the 
and 100 μmol L 
| Effects of MEM on thalamocortical glutamatergic transmission
Levels of MEM in the CNS are similar to those in plasma, 43 II-mGluR, which includes mGlu2R and mGlu3R, is widely expressed in brain tissues and inhibits the release of neurotransmitters. 47 Although mGlu3R is expressed in pre-and postsynaptic astroglial regions, mGlu2R is localized in the extra-synaptically axonal presynaptic terminal region. 47 III-mGluR, which includes mGlu4R, mGlu7R, and mGlu8R, is mainly expressed in excitatory presynaptic synapses, and mGlu6R is primarily expressed in the retina. 47 Activation of mGlu7R and mGluR8R suppresses thalamocortical transmission. 48 Therefore, the thalamocortical glutamatergic pathway receives two independent extra-synaptically inhibitory regulation mechanisms, and these are associated with Sxc/mGluR in the MDTN (Sxc/II-mGluR) and the mPFC (Sxc/II-mGluR/III-mGluR). ). 100 μmol L −1 cysteine-induced astroglial glutamate release was concentration-dependently enhanced by MEM (Logistic regression) tetrameric complexes comprising two obligatory NR1 and NR2 subunits that include the proteins NR2A, NR2B, NR2C, and NR2D. 52 The agents 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic-acid, phencyclidine, ketamine, and MK801 have affinity for NR2A, NR2B, NR2C, and NR2D subunits. 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic-acid has higher affinity for NR2B than for the other NR2 subunits, whereas phencyclidine, ketamine, and MK801 have higher affinity for NR2C than for other NR2 subunits. 52 Sxc exchanges extracellular cystine and intracellular glutamate across plasma membranes, and mediates a wide range CNS functions. 12 The import of cystine through Sxc produces glutathione as a precursor, 12 and exported glutamate plays important roles in extrasynaptic transmission. 23, 46 Several clinical studies show that NAC ameliorates cognitive dysfunctions in patients with early stage Alzheimer's disease, 56 severe schizophrenia, and bipolar disorder. 57 Preclinical studies also demonstrate that behavioral deficits in rat phencyclidine models are addressed by NAC treatments. 31 The 
| Candidate mechanisms of MEM
| CONCLUSIONS AND IMPLICATIONS
The present study demonstrates dual independent regulatory mecha- 
